Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET
Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET
复制标题
成骨肉瘤对新辅助治疗的反应：通过 18F-FDG-PET 评估
DOI：
10.1007/s12149-008-0147-y
复制
发表时间：
2008-07-01
影响因子：
2.6
通讯作者：
Lin, Nong
中科院分区：
文献类型：
--
作者：
Ye, Zhaoming;Zhu, Jiangjun;Lin, Nong
目的本研究的目的是评估f -18-氟-2-脱氧-d-葡萄糖正电子发射断层扫描（FDG-PET）在评估骨肉瘤化疗反应中的潜在作用，并将其与组织学评估的肿瘤坏死进行比较。方法对15例患者进行新辅助治疗前后的全身FDG-PET检查。采用化疗前后肿瘤的最大标准摄取值（SUVmax）和肿瘤与背景比（TBR）进行半定量PET成像分析。化疗前和化疗后的suvmax分别记录为suv1和SUV2。tbr1和tbr2代表化疗前和化疗后的TBR。TBR是通过在肿瘤和对侧正常肢体或骨盆上绘制相同的兴趣区域来计算的。肿瘤坏死按Salzer-Kuntschik标准分类。结果8例肿瘤坏死大于90%的患者反应良好，7例肿瘤坏死小于90%的患者反应不良。SUV2/SUV1、TBR2/TBR1、TBR2与肿瘤坏死程度显著相关（P< 0.01，P< 0.001，P< 0.001）。反应良好的患者TBR2/ tbr1均低于0.46，反应不良的患者TBR2/ tbr1均高于0.49。然而，很难区分SUV2/SUV1的良好反应和不良反应。结论sfdg - pet是一种很有前途的无创评估骨肉瘤化疗反应的工具。在本研究中，TBR优于SUVmaxin评价化疗反应。
ObjectiveThe aim of this study was to evaluate the potential role of F-18-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in assessing the chemotherapy response of osteosarcoma when compared with histologically assessed tumor necrosis.MethodsFifteen patients were examined with whole-body FDG-PET prior to and following neoadjuvant therapy. The maximum standard uptake value (SUVmax) of tumor and tumor to background ratio (TBR) prior to and following chemotherapy was used for semiquantitative PET imaging analysis. The SUVmaxof prechemotherapy and post-chemotherapy was recorded as SUV1and SUV2. TBR1and TBR2represented prechemotherapy and post-chemotherapy TBR. TBR was calculated by drawing an identical region of interest over the tumor and the contralateral normal limb or pelvis. Tumor necrosis was classified according to Salzer-Kuntschik’s criteria.ResultsEight patients with more than 90% tumor necrosis were classified as showing good responses and seven patients with less than 90% tumor necrosis as showing poor responses. SUV2/SUV1, TBR2/TBR1, and TBR2were significantly correlated with the tumor necrosis degree (P< 0.01,P< 0.001,P< 0.001). TBR2/TBR1were below 0.46 in all the patients with favorable responses, and higher than 0.49 in all the patients with unfavorable responses. However, it was difficult to distinguish good responses from poor responses by SUV2/SUV1.ConclusionsFDG-PET is a promising tool to assess the chemotherapy response of osteosarcoma noninvasively. The TBR was better than SUVmaxin evaluating the chemotherapy response in this study.